ProPhase Labs Inc. has released a presentation detailing its business verticals and initiatives. The presentation highlights ProPhase BioPharma's BE-Smart investigational esophageal cancer test, which aims to provide early detection for esophageal cancer with a target market of $7-14 billion. The company is working towards a strategic partnership with a major cancer diagnostic company and plans to commercialize the test either as a laboratory developed test (LDT) or in compliance with FDA requirements. Additionally, ProPhase Labs is involved in DNA Complete, focusing on Whole Genome Sequencing and Bioinformatics Direct-to-Consumer services. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.